Mobile technology–assisted maintenance therapy for children with acute lymphoblastic leukemia
Official title: A Randomized Controlled Trial of Mobile Technology-assisted Outpatient Maintenance Therapy in Children With Acute Lymphoblastic Leukaemia (ALL)
Run by Institute of Hematology & Blood Diseases Hospital, China · NCT07278882 · Data updated 2026-11-12
This study will try a mobile phone app with reminders and telemedicine scheduling to help children with acute lymphoblastic leukemia keep their medication dosing in the target range.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | Any age to 16 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Tianjin, Tianjin Municipality) |
| Status | Recruiting |
| Started | December 1, 2025 |
| Main results expected | November 20, 2027 |
| Study ends | November 20, 2027 |
| Registry record updated | October 20, 2026 |
| Trial ID | NCT07278882 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children diagnosed before age 16 who have already demonstrated at least three months of over 90% compliance using a mobile app to log daily medication and weekly blood tests, are no longer receiving in-hospital chemotherapy, and whose parent or legal guardian can provide informed consent.
✕Probably not a fit
Children who lack reliable mobile phone access or connectivity, who require ongoing in-hospital chemotherapy, or whose drug levels remain unpredictable despite adherence are unlikely to benefit from the intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Children with acute lymphoblastic leukemia who are completing outpatient maintenance therapy and have already shown high compliance with a mobile app will use a mobile-phone portal that schedules telemedicine clinic visits and sends periodic messages with instructions for follow-up blood testing and dose adjustment. The intervention combines remote reminders, logging of daily medication and weekly blood test results, and telemedicine scheduling to prompt timely dose modifications. The primary outcome is the percentage of time that drug dosing remains within the prespecified therapeutic target range. The study is conducted at the Institute of Hematology & Blood Diseases Hospital in Tianjin, China.
Why it matters
Potential benefit: If successful, this approach could increase the amount of time children keep their medication dosing within the therapeutic target, potentially reducing relapse risk and limiting toxicity from improper dosing.
How similar studies have gone: Previous studies using mobile reminders and telemedicine have improved medication adherence in pediatric chronic conditions, but applying these tools specifically to maintain chemotherapy drug levels in pediatric ALL is relatively novel and not yet widely proven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. \< 16 years old at diagnosis; 2. having demonstrated ≥ 3 months of \> 90% compliance with using a mobile app to log in records of daily medication and weekly blood test results; 3. no further in-hospital chemotherapy; 4. patient or legal guardian provides informed consent. Exclusion Criteria: None
Where it's running
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China Recruiting
Study contacts
- Study coordinator: Yahui Feng
- Email: fengyahui@ihcams.ac.cn
- Phone: 022-23909051
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
QLS4131 plus isatuximab for newly diagnosed primary plasma cell leukemia
This trial tests whether a BCMA/GPRC5D/CD3 trispecific antibody (QLS4131) added to isatuximab can help adults with newly diagnosed primary plasma cell leukemia see better treatment responses.
-
F182112 in relapsed/refractory autoimmune hemolytic anemia
A small early study tests F182112 as a single treatment for adults with AIHA that has not responded to other therapies, to see if it’s safe and what dose works best.
-
Multi-target drugs sequentially combine therapy in adults with newly diagnosed immune thrombocytopenia
This study tests whether starting with standard steroids plus a TPO-RA, then adding a second targeted therapy if needed, can improve platelet counts in adults with newly diagnosed ITP.
-
Isatuximab in adults with refractory severe aplastic anemia
This study tests whether the drug isatuximab can help adults with refractory severe aplastic anemia who have very low blood counts.
-
Zeprumetostat in relapsed/refractory T-cell large granular lymphocytic leukemia
This study tests whether taking Zeprumetostat by mouth can help people with relapsed or hard-to-treat T-cell large granular lymphocytic leukemia.
-
CM336 plus Isa-VR in newly diagnosed primary plasma cell leukemia
A new combination therapy using CM336 with isatuximab, lenalidomide, and bortezomib is being tested in adults newly diagnosed with primary plasma cell leukemia to see if it can improve treatment responses and safety.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.